The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study
Abstract
PURPOSE: To assess progression-free survival (PFS) and overall survival (OS) in patients with suboptimally debulked epithelial ovarian cancer receiving cisplatin (100 mg/m 2) or 24-hour infusion paclitaxel (200 mg/m 2) or the combination of paclitaxel (135 mg/m 2) followed by cisplatin (75 mg/m 2). PATIENTS AND METHODS: After stratification for disease measurability, patients were randomized to receive six cycles of one of the treatments every 3 weeks. If measurable, complete response (CR) or partial response (PR) was determined. RESULTS: Six hundred fourteen of 648 patients who entered onto the trial were eligible. Monotherapies were discontinued more frequently (cisplatin because of toxicity or patient refusal [17%], and paclitaxel because of progression [20%]) compared with the combination therapy (7% and 6%, respectively). Neutropenia, fever, and alopecia were more severe with paclitaxel-containing regimens; whereas anemia, thrombocytopenia, neurotoxicity, nephrotoxicity, and gastrointestinal toxicity were more severe with cisplatin-containing regimens. The CR/PR rates on paclitaxel monotherapy were significantly lower compared with the cisplatin regimens (42% v 67%, respectively; P < .001). The relative hazard (RH) of first progression or death was significantly greater among those randomized to paclitaxel (RH = 1.41; 95% confidence interval [CI], 1.15 to 1.73; P < .001) when compared with cisplatin; however, RH did not differ significantly between the two cisplatin regimens (RH = 1.06; 95% CI, 0.895 to 1.30). Relative to cisplatin, the death rate on paclitaxel was 15% greater (RH = 1.15; 95% CI, 0.929 to 1.42), and the death rate on the combination treatment was 1% less (RH = 0.99; 95% CI, 0.795 to 1.23). These differences among treatment groups were not statistically significant (P = .31). CONCLUSION: Cisplatin alone or in combination yielded superior response rates and PFS relative to paclitaxel. However, OS was similar in all three arms, and the combination therapy had a better toxicity profile. Therefore, the combination of cisplatin and paclitaxel remains the preferred initial treatment option.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Practical Nonparametric Statistics
Groggel, D. J. (2000) · Technometrics · doi:10.1080/00401706.2000.10486067 · Cited by 11,041
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Self-citationMcGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., & Donehower, R. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-273 · Cited by 1,100
Thigpen, J. T., Blessing, J. A., Ball, H., Hummel, S. J., & Barrett, R. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1748 · Cited by 372
Omura, G., Blessing, J. A., Ehrlich, C. E., Miller, A., Yordan, E., Creasman, W. T., & Homesley, H. D. (1986) · Cancer · doi:10.1002/1097-0142(19860501)57:9<1725::aid-cncr2820570903>3.0.co;2-j · Cited by 278
McGuire, W. P., Hoskins, W. J., Brady, M. F., Homesley, H. D., Creasman, W. T., Berman, M. L., Ball, H., Berek, J. S., & Woodward, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1589 · Cited by 213
Self-citation
Cited by
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1123 · Cited by 1,154
Piccart, M. J. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.699 · Cited by 981
Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
Winter, W. E., Maxwell, G. L., Tian, C., Carlson, J. W., Ozols, R. F., Rose, P. G., Markman, M., Armstrong, D. K., Muggia, F., & McGuire, W. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2517 · Cited by 845
Self-citationRecent progress in the diagnosis and treatment of ovarian cancer
Jelovac, D., & Armstrong, D. K. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20113 · Cited by 765
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.-M., Cristea, M., DeRosa, M., Eisenhauer, E. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0007 · Cited by 715
Self-citationBookman, M. A., Brady, M. F., McGuire, W. P., Harper, P. G., Alberts, D. S., Friedlander, M., Colombo, N., Fowler, J. M., Argenta, P. A., De Geest, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1684 · Cited by 705
Self-citationHennessy, B. T., Coleman, R. L., & Markman, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61338-6 · Cited by 640
Chi, D. S., Eisenhauer, E. L., Zivanovic, O., Sonoda, Y., Abu-Rustum, N. R., Levine, D. A., Guile, M. W., Bristow, R. E., Aghajanian, C., & Barakat, R. R. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.03.018 · Cited by 591
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Sharma, S. V., Haber, D. A., & Settleman, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2820 · Cited by 586
New tumor markers: CA125 and beyond
BAST, R. C., BADGWELL, D., LU, Z., MARQUEZ, R., ROSEN, D., LIU, J., BAGGERLY, K. A., ATKINSON, E. N., SKATES, S., ZHANG, Z., et al. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00441.x · Cited by 504
Panici, P. B., Maggioni, A., Hacker, N., Landoni, F., Ackermann, S., Campagnutta, E., Tamussino, K., Winter, R., Pellegrino, A., Greggi, S., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji102 · Cited by 465
Markman, M., Liu, P. Y., Wilczynski, S., Monk, B., Copeland, L. J., Alvarez, R. D., Jiang, C., & Alberts, D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.013 · Cited by 447
Self-citation(ICON1), I. C. O. N. 1., & European Organisation for Research and Treatment of Cancer Collaborators–Adjuvant ChemoTherapy In Ovarian Neoplasm (EORTC–ACTION) (2003) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.105 · Cited by 443
Chang, S.-J., Hodeib, M., Chang, J., & Bristow, R. E. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.05.040 · Cited by 433
Optimal primary surgical treatment for advanced epithelial ovarian cancer
Elattar, A., Bryant, A., Winter-Roach, B. A., Hatem, M., & Naik, R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007565.pub2 · Cited by 403
Markman, M., & Mekhail, T. M. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.6.755 · Cited by 375
Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo
Fellner, S., Bauer, B., Miller, D. S., Schaffrik, M., Fankhänel, M., Spruß, T., Bernhardt, G., Graeff, C., Färber, L., Gschaidmeier, H., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15451 · Cited by 359
Crown, J., & O'Leary, M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02074-2 · Cited by 352
Mucinous Epithelial Ovarian Cancer: A Separate Entity Requiring Specific Treatment
Hess, V., A'Hern, R., Nasiri, N., King, D. M., Blake, P. R., Barton, D. P. J., Shepherd, J. H., Ind, T., Bridges, J., Harrington, K., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.078 · Cited by 333
Diagnosis and Treatment of Ovarian Cancer
Orr, B., & Edwards, R. P. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.010 · Cited by 322
Therapeutic strategies in epithelial ovarian cancer
Kim, A., Ueda, Y., Naka, T., & Enomoto, T. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-14 · Cited by 319
Epithelial Ovarian Cancer: A Review of Current Management
Guppy, A. E., Nathan, P. D., & Rustin, G. J. S. (2005) · Clinical Oncology · doi:10.1016/j.clon.2005.05.009 · Cited by 311
Focus on epithelial ovarian cancer
Ozols, R. F., Bookman, M. A., Connolly, D. C., Daly, M. B., Godwin, A. K., Schilder, R. J., Xu, X., & Hamilton, T. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00002-9 · Cited by 294
Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary
Gershenson, D. M., Sun, C. C., Lu, K. H., Coleman, R. L., Sood, A. K., Malpica, A., Deavers, M. T., Silva, E. G., & Bodurka, D. C. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000227787.24587.d1 · Cited by 290
Tewari, D., Java, J. J., Salani, R., Armstrong, D. K., Markman, M., Herzog, T., Monk, B. J., & Chan, J. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9898 · Cited by 288
Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy
Romero, I., & Bast, R. C. (2012) · Endocrinology · doi:10.1210/en.2011-2123 · Cited by 286
Treatment goals in ovarian cancer
Ozols, R. F. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.15351.x · Cited by 252
Kyrgiou, M., Salanti, G., Pavlidis, N., Paraskevaidis, E., & Ioannidis, J. P. A. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj443 · Cited by 187
Management strategies for recurrent platinum-resistant ovarian cancer
Naumann, R. W., & Coleman, R. L. (2011) · Drugs · doi:10.2165/11591720-000000000-00000 · Cited by 152
Considering Usual Medical Care in Clinical Trial Design
Dawson, L., Zarin, D. A., Emanuel, E. J., Friedman, L. M., Chaudhari, B., & Goodman, S. N. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000111 · Cited by 93
Mahner, S., Meier, W., du Bois, A., Brown, C., Lorusso, D., Dell’Anna, T., Cretin, J., Havsteen, H., Bessette, P., Zeimet, A. G., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.11.017 · Cited by 70
Integrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129
Metadata
- Authors
- Muggia, F. M., Braly, P. S., Brady, M. F., Sutton, G., Niemann, T. H., Lentz, S. L., Alvarez, R. D., Kucera, P. R., & Small, J. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-01-01
- Volume
- 18
- Issue
- 1
- Pages
- 106-106
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1863225814
- Cited by
- 601
- References
- 14
- FWCI
- 40.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.